IL186445A0 - Dna-pk inhibitors - Google Patents

Dna-pk inhibitors

Info

Publication number
IL186445A0
IL186445A0 IL186445A IL18644507A IL186445A0 IL 186445 A0 IL186445 A0 IL 186445A0 IL 186445 A IL186445 A IL 186445A IL 18644507 A IL18644507 A IL 18644507A IL 186445 A0 IL186445 A0 IL 186445A0
Authority
IL
Israel
Prior art keywords
inhibitors
dna
Prior art date
Application number
IL186445A
Other languages
English (en)
Original Assignee
Kudos Pharm Ltd
Cancer Rec Tech Ltd
Smith Graeme Cameron Murray
Martin Niall Morrisson Barr
Cockcroft Xiao Ling Fan
Menear Keith Allan
Hummersone Marc Geoffrey
Griffin Roger John
Golding Bernard Thomas
Newell David Richard
Calvert Hilary Alan
Curtin Nicola Jane
Hardcastle Ian Robert
Saravanan Kappusamy
Marine Desage El Murr
Frigerio Mark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0507831A external-priority patent/GB0507831D0/en
Application filed by Kudos Pharm Ltd, Cancer Rec Tech Ltd, Smith Graeme Cameron Murray, Martin Niall Morrisson Barr, Cockcroft Xiao Ling Fan, Menear Keith Allan, Hummersone Marc Geoffrey, Griffin Roger John, Golding Bernard Thomas, Newell David Richard, Calvert Hilary Alan, Curtin Nicola Jane, Hardcastle Ian Robert, Saravanan Kappusamy, Marine Desage El Murr, Frigerio Mark filed Critical Kudos Pharm Ltd
Publication of IL186445A0 publication Critical patent/IL186445A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
IL186445A 2005-04-15 2007-10-07 Dna-pk inhibitors IL186445A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67183005P 2005-04-15 2005-04-15
US67188605P 2005-04-15 2005-04-15
GB0507831A GB0507831D0 (en) 2005-04-18 2005-04-18 DNA-PK inhibitors
US69606405P 2005-07-01 2005-07-01
US71890405P 2005-09-20 2005-09-20
PCT/GB2006/001369 WO2006109081A1 (en) 2005-04-15 2006-04-13 Dna-pk inhibitors

Publications (1)

Publication Number Publication Date
IL186445A0 true IL186445A0 (en) 2008-01-20

Family

ID=36579227

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186445A IL186445A0 (en) 2005-04-15 2007-10-07 Dna-pk inhibitors

Country Status (13)

Country Link
US (2) US20060264623A1 (OSRAM)
EP (2) EP1869040A1 (OSRAM)
JP (2) JP2008535902A (OSRAM)
KR (1) KR20080002963A (OSRAM)
AR (2) AR053358A1 (OSRAM)
AU (1) AU2006235731A1 (OSRAM)
CA (1) CA2603637A1 (OSRAM)
IL (1) IL186445A0 (OSRAM)
MX (1) MX2007012696A (OSRAM)
NO (1) NO20075809L (OSRAM)
TW (2) TW200720274A (OSRAM)
UY (1) UY29479A1 (OSRAM)
WO (2) WO2006109084A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
ATE461193T1 (de) * 2003-08-13 2010-04-15 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
TW200616986A (en) 2004-09-20 2006-06-01 Kudos Pharm Ltd DNA-pk inhibitors
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Atm阻害剤
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
WO2010136778A1 (en) * 2009-05-29 2010-12-02 Kudos Pharmaceuticals Limited Dibenzothiophene derivatives as dna- pk inhibitors
JP5663571B2 (ja) 2009-07-02 2015-02-04 サノフイ 新規2,3−ジヒドロ−1H−イミダゾ{1,2−a}ピリミジン−5−オン誘導体、これらの調製およびこれらの薬学的使用
JP5680638B2 (ja) 2009-07-02 2015-03-04 サノフイ 新規な(6−オキソ−1,6−ジヒドロピリミジン−2−イル)アミド誘導体、この調製およびakt(pkb)リン酸化インヒビターとしてのこの医薬的な使用
RU2561130C2 (ru) 2009-07-02 2015-08-20 Санофи НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2947548B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
JP5680639B2 (ja) * 2009-07-02 2015-03-04 サノフイ 新規6−モルホリン−4−イル−ピリミジン−4−(3h)−オン誘導体、およびakt(pkb)リン酸化阻害剤としてのこの医薬調製物
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2951170B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
US9618663B2 (en) 2010-04-15 2017-04-11 3M Innovative Properties Company Retroreflective articles including optically active areas and optically inactive areas
WO2011137428A1 (en) * 2010-04-30 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating hiv infection: inhibition of dna dependent protein kinase
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
EP2658844B1 (fr) 2010-12-28 2016-10-26 Sanofi Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
ES2637829T3 (es) * 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
US10287285B2 (en) * 2014-12-02 2019-05-14 Prana Biotechnology Limited 4H-pyrido[1,2-A]pyrimidin-4-one compounds
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna損傷剤とdna−pk阻害剤との組合せ物を使用する、がんを処置するための方法
CN109232476B (zh) * 2018-11-06 2020-06-26 常州大学 一种制备n-苯基-3-吗啡啉丙酰胺的方法
US20230111712A1 (en) * 2020-03-13 2023-04-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Stable reactive compositions for bioconjugation, probes, and protein labeling
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (OSRAM) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
HUT58310A (en) 1988-12-21 1992-02-28 Upjohn Co Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
ES2106783T3 (es) 1990-06-20 1997-11-16 Upjohn Co 1-benzopiran-4-onas y 2-amino-1,3-benzoxacin-4-onas antiarterosclerosis y antitromboticas.
WO1992000290A1 (en) 1990-06-29 1992-01-09 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
WO1994005283A1 (fr) 1992-09-02 1994-03-17 Kyowa Hakko Kogyo Co., Ltd. Medicament anti-vih
ATE203904T1 (de) * 1993-04-09 2001-08-15 Toyama Chemical Co Ltd Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
AU1461197A (en) 1995-11-16 1997-06-05 Icos Corporation Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
WO1998055602A1 (en) 1997-06-06 1998-12-10 Mayo Foundation For Medical Education And Research Screening for phosphatidylinositol related-kinase inhibitors
AU8068198A (en) 1997-06-13 1998-12-30 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
AU3042601A (en) * 2000-01-24 2001-07-31 Thrombogenix Pty Ltd Therapeutic morpholino-substituted compounds
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
JP4458746B2 (ja) 2001-01-16 2010-04-28 グラクソ グループ リミテッド 癌の治療方法
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6894055B2 (en) 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
BR0307944A (pt) 2002-02-25 2005-02-01 Kudos Pharm Ltd Piranonas úteis como inibidores de atm
ES2357057T3 (es) * 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
ATE461193T1 (de) * 2003-08-13 2010-04-15 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
TW200616986A (en) * 2004-09-20 2006-06-01 Kudos Pharm Ltd DNA-pk inhibitors
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Atm阻害剤
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Also Published As

Publication number Publication date
UY29479A1 (es) 2006-11-30
JP2008535903A (ja) 2008-09-04
AU2006235731A1 (en) 2006-10-19
KR20080002963A (ko) 2008-01-04
EP1869040A1 (en) 2007-12-26
WO2006109084A1 (en) 2006-10-19
AR054438A1 (es) 2007-06-27
US20060264427A1 (en) 2006-11-23
US7696203B2 (en) 2010-04-13
AR053358A1 (es) 2007-05-02
MX2007012696A (es) 2008-03-14
JP2008535902A (ja) 2008-09-04
US20060264623A1 (en) 2006-11-23
TW200720274A (en) 2007-06-01
CA2603637A1 (en) 2006-10-19
TW200720271A (en) 2007-06-01
EP1869021A1 (en) 2007-12-26
NO20075809L (no) 2007-12-27
WO2006109081A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
IL186445A0 (en) Dna-pk inhibitors
IL181969A0 (en) Dna-pk inhibitors
IL185185A0 (en) Azolylacylguanidines as ??-secretase inhibitors
IL190078A0 (en) Kinase inhibitors
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
ZA200900109B (en) Pyrrolotriazine kinase inhibitors
IL188617A0 (en) Glutamate aggrecanase inhibitors
IL184303A0 (en) Amino-pyridines as inhibitors of ??-secretase
GB0619753D0 (en) Enzyme inhibitors
IL191997A0 (en) Inhibitors of iap
IL179398A0 (en) Dpp-ib inhibitors
IL194339A0 (en) Enzyme inhibitors
IL177037A (en) Kimase inhibitors
PL1943243T3 (pl) Inhibitory kinazy
IL190081A0 (en) Nnrt inhibitors
EP1912639A4 (en) Thiazolopyrimidine KINASE INHIBITORS
GB0421355D0 (en) Inhibitors
GB0608844D0 (en) Enzyme inhibitors
GB0421356D0 (en) Inhibitors
GB0617161D0 (en) Enzyme inhibitors
ZA200705383B (en) Benzoyl-tetrahydropyridine as GlyT-1 inhibitors
GB0516967D0 (en) Inhibitors
ZA200709467B (en) DNA-PK inhibitors
GB0507831D0 (en) DNA-PK inhibitors